Hyperglycemia is commonly observed during acute and critical illness. Recent studies have investigated the risk of developing diabetes after acute and critical illness, but the relationship between degree of in-hospital hyperglycemia and new-onset diabetes has not been investigated. This study examines the evidence for the relationship between in-hospital hyperglycemia and prevalence of new-onset diabetes after acute and critical illness. A literature search was performed of the MEDLINE, EMBASE, and Scopus databases for relevant studies published from January 1, 2000, through August 4, 2016. Patients with no history of diabetes before hospital discharge were included in the systematic review. In-hospital glucose concentration was classified as normoglycemia, mild hyperglycemia, or severe hyperglycemia for the metaanalysis. Twenty-three studies were included in the systematic review, and 18 of these (111,078 patients) met the eligibility criteria for the meta-analysis. The prevalence of new-onset diabetes was significantly related to in-hospital glucose concentration and was 4% (95% CI, 2%-7%), 12% (95% CI, 9%-15%), and 28% (95% CI, 18%-39%) for patients with normoglycemia, mild hyperglycemia, and severe hyperglycemia, respectively. The prevalence of new-onset diabetes was not influenced by disease setting, follow-up duration, or study design. In summary, this study found stepwise growth in the prevalence of new-onset diabetes with increasing in-hospital glucose concentration. Patients with severe hyperglycemia are at the highest risk, with 28% developing diabetes after hospital discharge. 
A cute and critical illness describes a group of life-threatening conditions that affect millions of people around the world every year. In 2013 alone, 8.6 million people experienced acute myocardial infarction, 10.3 million stroke, 17.2 million pancreatitis, and 33.4 million burns. 1 The mortality of acute and critical illness ranges from 7% in patients with ST-segment elevation myocardial infarction to 50% to 60% in patients with septic shock. 2 In addition, acute and critical illness carries a large economic burden, with the average cost of treatment in an intensive care unit ranging from $4000 to $8500 per day. 3, 4 Moreover, the global burden of acute and critical illness is expected to increase as the population ages and nonfatal outcomes require more resources from health care systems. 1 Transient elevations in blood glucose concentration during acute and critical illness have been recognized for decades. 5, 6 This response in patients without a known history of diabetes was classically considered benign 7, 8 and commonly referred to as stress hyperglycemia. 9 In recent years, the focus has shifted from immediate health outcomes to long-term outcomes, including the development of new-onset diabetes after acute and critical illness. Several studies have reported that acute and critically ill patients may have a greater risk of subsequent diabetes than the general population. 10, 11 However, evidence is conflicting, 12 even within the same disease setting. 13, 14 A recent systematic review found that hyperglycemia in patients admitted to intensive care units was associated with an increased risk of subsequent diabetes 15 ; however, this association has not been explored in broader settings of acute and critical illness. In addition, the relationship between degree of hyperglycemia and development of new-onset diabetes remains largely unknown. Therefore, the aim of this study was to systematically review the best available evidence on the relationship between degree of in-hospital hyperglycemia and prevalence of new-onset diabetes after acute and critical illness.
METHODS Search Criteria and Identification
A search strategy was developed to identify all clinical studies that reported the prevalence of new-onset diabetes after hospital discharge following acute and critical illness. Three major electronic databases (MEDLINE, EMBASE, and Scopus) were searched to identify relevant literature from January 1, 2000, through August 4, 2016 . The following key words were searched: (blood glucose or hyperglycemia) AND diabetes AND (acute or critically) ill AND clinical studies AND (predict or risk) AND hospital. See the Supplemental Appendix (available online at http://www.mayoclinicproceedings. org) for the full search strategy. Abstracts were reviewed for relevance, and full-text articles were obtained for potentially eligible studies. References in the included studies were also reviewed for eligibility.
Eligibility Criteria
The study inclusion criteria were diabetes onset after hospitalization, no history of diabetes (including the need for insulin therapy or oral hypoglycemic agents during hospitalization), older than 17 years, and hospital admission with acute and critical illness. The study exclusion criteria were in-hospital glucose concentration not reported, pediatric or transplant patients, and reviews, commentaries, and letters to the editor.
If data from the same cohort had been reported in multiple studies, only the most recent study or the most detailed population (with respect to relevant methods and results) was included. Eligibility assessment was conducted by 2 of us (C.J.J. and V.M.A.), and discrepancies were resolved by discussion with the senior author (M.S.P.) or via e-mail with authors of primary studies.
Data Extraction and Reporting
Data were extracted from all eligible studies and entered into a predesigned data collection form. The following study and patient characteristics were extracted: author(s), year of publication, country, study design, disease setting, follow-up duration, total study population, age, percentage males, number of patients who met the inclusion criteria, in-hospital glucose categorization, and prevalence of new-onset diabetes. Patients with incomplete data sets were not eligible for analysis (ie, patients unable to complete follow-up or without an in-hospital glucose concentration measured). For studies that included patients with and without diabetes or that had multiple study arms, only patients without a history of diabetes, an in-hospital diabetes diagnosis (including those discharged on insulin therapy), or a need for intensive glucoselowering therapy during hospitalization were eligible for analysis. The conventional treatment arms of randomized controlled trials were considered prospective cohorts for the purpose of this systematic review.
Reporting of this study was in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses Protocols statement and checklist. 16 
Quality Assessment
The methodological quality of studies was assessed by the Newcastle-Ottawa Scale. 17 Studies were allocated a maximum of 9 points based on 3 perspectives of study design: the selection of the study groups, the comparability of the study groups, and the ascertainment of the outcome of interest. Studies were considered to be of high quality if 5 or more points were scored and of low quality if 4 or fewer points were scored. 18 New-Onset Diabetes. New-onset diabetes was defined as diabetes diagnosed after hospital discharge for patients with no history of diabetes. Patients receiving insulin therapy or oral hypoglycemic agents at hospital discharge were deemed to have preexisting diabetes and were not included in the analysis.
ARTICLE HIGHLIGHTS
In-hospital Glycemia. Patients were categorized into normoglycemia, mild hyperglycemia, and severe hyperglycemia groups according to in-hospital glucose concentration.
Normoglycemia. Because ADA and World Health Organization guidelines for normoglycemia differ (FPG level <100 mg/dL and <110 mg/dL, respectively), 19, 20 patients were classified as having normoglycemia according to author-reported guidelines. If the criteria for glucose classification were not specified by the authors, the ADA guidelines were applied. 20 Thus, normoglycemia was defined as an FBG level less than 100 mg/dL or a random or 2-hour PG level less than 140 mg/dL.
Mild Hyperglycemia. Patients with authordefined impaired fasting glucose levels or impaired glucose tolerance, FPG levels of 100 to 125 mg/dL, or random or 2-hour PG levels of 140 to 199 mg/dL were classified as having mild hyperglycemia.
Severe Hyperglycemia. Patients with inhospital FPG levels of 126 mg/dL or greater or random or 2-hour PG levels of 200 mg/dL or greater without preexisting diabetes were classified as having severe hyperglycemia.
Statistical Analyses
Proportion meta-analyses were conducted to determine the pooled prevalence of new-onset diabetes in patients after acute and critical illness. Studies with patients who could be categorized by in-hospital glucose concentration were eligible for analysis. Data were pooled using statistical software (StatsDirect Version 3.0 for Windows; StatsDirect Ltd). Forest plots of pooled prevalence with 95% CIs were generated for all analyses, and a random effects model was applied to provide the most conservative estimate of new-onset diabetes prevalence. If there was no overlap in CIs, the difference between groups was considered statistically significant (P<.05). A sensitivity analysis was also conducted by removing 1 study at a time from the metaanalysis and recalculating the summary effect. Heterogeneity across studies was assessed by the Cochran Q statistic at a significance level of P<.10 and quantified by I 2 , with cutoff values of 25%, 50%, and 75% indicating low, moderate, and high heterogeneity, respectively. 21, 22 Publication bias was assessed by the BeggMazumdar, Egger, and Harbord tests, with P<.05 considered statistically significant.
A meta-analysis was conducted to investigate the relationship between degree of inhospital hyperglycemia and prevalence of new-onset diabetes. If in-hospital glucose concentrations did not align with the criteria for normoglycemia, mild hyperglycemia, or severe hyperglycemia, data were fit into the most appropriate category. Subgroup analyses were also conducted. One subgroup analysis investigated the effect of different acute disease settings on the prevalence of new-onset diabetes. A particular acute disease setting was included in this analysis if specified in 2 or more studies. Another subgroup analysis investigated the effect of follow-up duration on the prevalence of new-onset diabetes. Studies were categorized arbitrarily into follow-up intervals of less than 24 months, 24 to 48 months, and greater than 48 months. The reported follow-up duration was assumed to be the mean, unless stated otherwise. If studies reported multiple followup intervals, the longest duration or the most complete data set was used. A third subgroup analysis investigated the effect of study design on the prevalence of new-onset diabetes. For the purpose of this review, the conventional arms of randomized controlled trials were classified as prospective cohorts.
RESULTS

Study Identification
A total of 1138 potentially relevant articles were identified and screened. Of these, 50 articles were assessed for eligibility, and 23 were included in the systematic review ( Figure 1) . [10] [11] [12] [13] [14] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] Eighteen of the 23 included articles were eligible for metaanalysis of new-onset diabetes by in-hospital glucose concentration. [11] [12] [13] [14] 23, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] 38, 40 Study Characteristics A total of 121,501 patients were identified in the 23 included studies, with 52.8% being male (Table 1) . Data for 111,078 patients who completed follow-up and had no history of diabetes before hospital discharge were eligible for meta-analysis.
Quality Assessment and Publication Bias
The Newcastle-Ottawa Scale of methodological quality was applied to each of the studies ( Table 2 ). The median score was 8 (range, [6] [7] [8] , and all the studies were considered high quality. There was no evidence of publication bias using the Begg-Mazumdar (P¼.55), Egger (P¼.15), and Harbord (P¼.11) tests.
In-hospital Hyperglycemia
The pooled prevalence of new-onset diabetes was 8% (95% CI, 6%-11%), and the sensitivity analysis after removal of each study did not change it significantly. The association between in-hospital normoglycemia and prevalence of subsequent diabetes was reported in 17 studies, and these patients had a prevalence of 4% (95% CI, 2%-7%) (Figure 2A) . 11, 13, 14, 23, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] 38, 40 The association between in-hospital mild hyperglycemia and prevalence of subsequent diabetes was reported in 18 studies, and these patients had a prevalence of 12% (95% CI, 9%-15%) ( Figure 2B) . [11] [12] [13] [14] 23, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] 38, 40 The association between in-hospital severe hyperglycemia and prevalence of subsequent diabetes was reported in 5 studies, and the prevalence of new-onset diabetes for patients with severe hyperglycemia was 28% (95% CI, 18%-39%) ( Figure 2C) . 11, 27, 33, 34, 38 The absence of overlapping CIs indicated a significant difference between the groups (P<.05). Statistical heterogeneity was high for all the glycemic groups (Q: P<.001 for each group; I 2 : 98.7%, 95.4%, and 92.5% for normoglycemia, mild hyperglycemia, and severe hyperglycemia groups, respectively).
Effect of Disease Setting
The 18 meta-analyzed studies were conducted in 7 disease settings. Nine studies included patients with myocardial infarction, 13 patients. 28 Of the disease settings, myocardial infarction, stroke, and heart failure were suitable for meta-analysis. The pooled prevalence of new-onset diabetes was 7% (95% CI, 4%-9%) for myocardial infarction, 13% (95% CI, 7%-20%) for stroke, and 13% (95% CI, 12%-14%) for heart failure.
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Effect of Follow-up Duration
The prevalence of new-onset diabetes increased with follow-up duration; however, the trend was not statistically significant. Of the 18 studies, 11 had a follow-up duration of less than 24 months, and the prevalence of newonset diabetes in this timeframe was 7% (95% CI, 5%-10%). [12] [13] [14] 23, 26, 28, 31, 32, 36, 38, 40 Two studies had a follow-up duration of 24 to 48 months, and the prevalence was also 7% (95% CI, 1%-20%).
11,34 A further 5 studies had a follow-up duration longer than 48 months, and the prevalence was 9% (95% CI, 8%-11%).
27,29,30,33,35
Effect of Study Design
Of the 18 studies included in the meta-analyses, 13 were prospective cohorts [12] [13] [14] 23, 26, [28] [29] [30] [31] [32] [33] 38, 40 and 5 were retrospective cohorts. 11, 27, [34] [35] [36] There was no statistically significant difference in the prevalence of new-onset diabetes by study design, with the prevalence being 8% (95% CI, 6%-11%) for prospective cohort studies and 7% (95% CI, 3%-12%) for retrospective cohort studies.
DISCUSSION
This systematic review summarizes all available clinical evidence on the association between degrees of in-hospital glucose concentration and subsequent onset of diabetes in acute and critically ill patients. Twentythree studies with more than 120,000 patients were included in the systematic review. In the meta-analysis, the combined prevalence of new-onset diabetes was 8%, and this estimate depended on the degree of in-hospital hyperglycemia. Prevalence did not seem to be influenced by acute disease setting, follow-up duration, or study design. The patients included in this review were relatively homogenous and comprised acute and critically ill adults with no history of diabetes before hospital discharge and no glucose-lowering medications during hospitalization. In addition, all included patients were treated conventionally during hospitalization, and none of the studies included in the metaanalysis were interventional.
This systematic review and meta-analysis suggests that the degree of in-hospital hyperglycemia in acute and critically ill patients increases susceptibility to new-onset diabetes after hospitalization. We found a stepwise increase in the prevalence of new-onset diabetes, with 28% of patients with severe hyperglycemia developing new-onset diabetes after hospital discharge. This is strikingly higher than the 8.5% global prevalence of diabetes in adults. 41 Diabetes is a growing epidemic and is used as an encompassing term for diseases associated with elevated blood glucose concentrations. Conventional risk factors for diabetes have been investigated in the general population for decades, 42 and subtypes of diabetes, such as gestational and pancreatogenic diabetes, are well established. 43, 44 Recently, evidence has emerged about diabetes after myocardial infarction, stroke, and other acute and critical illness. 11, 24, 34, 36, 45 The outcomes of these studies suggest that the stress of acute and critical illness tips glucose homeostasis over the edge in susceptible patients and contributes to overt diabetes later in life. A systematic review of patients with acute pancreatitis found that the prevalence of new-onset diabetes is 23% at 5 years after the first episode of acute pancreatitis, 18 and this is similar to the 28% prevalence of newonset diabetes in the severe hyperglycemia group. However, that study did not investigate the concentration-dependent increase in risk of diabetes and was restricted to only 1 disease setting. The findings of the present study suggest that in-hospital hyperglycemia is not benign 7 and raises the question as to whether this represents an unrecognized subtype of diabetes or a new risk factor for type 2 diabetes mellitus. Prospective observational studies are now warranted to determine whether acute and critical illness is a causative factor for the development of new-onset diabetes.
Stress in acute and critical illness is a systemic response to injury or infection 46 characterized by a rise in PG, pro-inflammatory cytokine, and counterregulatory hormone levels ( Figure 3) . 47 Stress-induced hypermetabolism and inflammation can disturb carbohydrate metabolism by increasing hepatic glucose production, decreasing peripheral glucose uptake, and promoting insulin resistance in the liver and skeletal muscles. 46, 47 The subsequent hyperinsulinemia and hyperglycemia exacerbates inflammatory and Choi et al, 23 2005
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Combined A C B FIGURE 2. A, Prevalence of new-onset diabetes for patients with normoglycemia. Normoglycemia was classified as a hospital admission plasma glucose (PG) level less than 124 mg/dL (to convert to mmol/L, multiply by 0.0555) in the study by McAllister et al. 34 B, Prevalence of new-onset diabetes for patients with mild hyperglycemia. Patients with random PG levels of 140 mg/dL or greater were classified as having mild hyperglycemia in the studies by Van Ackerbroeck et al, 28 Gornik et al, 30 and Shore et al 36 because data were not available for patients with severe hyperglycemia (random PG levels !200 mg/dL). Mild hyperglycemia was classified as a hospital admission PG level of 126 to 198 mg/dL in the study by McAllister et al 34 and 128 mg/dL or greater in the study by Meisinger et al. 35 C, Prevalence of new-onset diabetes for patients with severe hyperglycemia.
counterregulatory hormone responses, impeding the insulin signalling pathway and maintaining hyperglycemia. 9 It is generally believed that blood glucose levels peak several days after the initial insult and then return to normal during recovery. 46, 48 Recently, several authors have suggested that this stress signaling associated with transient hyperglycemia can continue after hospital discharge. 49 This is thought to relate to glycemic memory and is used to explain the development of diabetes. 50, 51 Hyperglycemia stimulates the production of reactive oxygen species that activate cell signaling pathways involving the nuclear factor-kb transcription factor and formation of nitrogen oxide and lipid peroxides. 52, 53 Although reactive oxygen species have short half-lives, the damage to protein and lipids can persist and, once modified, can exert altered cellular function over a prolonged period. 54 This contributes to the systemic inflammatory response and insulin resistance that characterizes acute and critical illness. Furthermore, hyperglycemia can lead to changes in gene expression. Epigenetic changes, such as DNA methylation and histone acetylation, can modulate antioxidant and inflammatory genes, also contributing to a Acute and critical stress is a systemic response to injury associated with hypermetabolism and increased circulating glucose, cytokine, and counterregulatory hormone levels. b Overt in-hospital stress hyperglycemia is characterized by disturbed carbohydrate metabolism, peripheral insulin resistance, and decreased insulin secretion.
c Gut injury results in impaired motility, disturbed barrier function, luminal translocation of bacteria, or altered endocrine and immune function.
d Persistent stress signaling describes the production of reactive oxygen species, DNA methylation and histone acetylation, and modulation of anti-inflammatory and antioxidant genes.
e Altered microbiota can lead to the loss of health-promoting bacteria and the proliferation of pathogenic bacteria. Pathogenic bacteria may promote further gut dysfunction (dashed arrow). NF-kB ¼ nuclear factor-kb; SCFA ¼ short-chain fatty acid.
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systemic inflammation. [51] [52] [53] 55 DNA methylation has been linked to human insulin secretion and resistance, 56 and the level of DNA methylation has been found to be a predictive biomarker of diabetes susceptibility, diagnosis, and progression. 53 The presence of systemic inflammation and insulin resistance might be exacerbated by gut injury, which is a common feature of acute and critical illness (Figure 3) . Changes in gut motility, barrier function, microbial composition, or endocrine function have been noted in various disease settings. [57] [58] [59] [60] [61] [62] Moreover, a meta-analysis of acute pancreatitis studies indicated that 3 in every 5 patients have evidence of gut barrier dysfunction, independent of disease severity. 63 Disturbances in gut barrier function are thought to include translocation of luminal bacteria and bacterial products, 64 reflecting changes in the composition of intestinal microbiota. 65, 66 This may lead to a loss of normal health-promoting commensal microbes and overgrowth of pathogenic bacteria. 60 Proliferation of unfavorable microbiota during acute and critical illness may result in a reduction of short-chain fatty acid production, prolonged exposure to bacterial endotoxins, and increased exposure to circulating proinflammatory factors. 67 These changes in the gut associated with inflammation and insulin resistance may increase a patient's susceptibility to diabetes later in life. 68 Furthermore, gut injury during acute and critical illness can affect the circulating concentration of regulatory peptides produced by the pancreas, gut, and adipose tissues. 62, 69 Variations in adipokines, gut peptides, and pancreatic hormones have been associated with disturbances in glucose metabolism and future risk of diabetes. [70] [71] [72] [73] However, no prospective cohort studies have specifically measured changes in these peptides from baseline to follow-up in acute and critically ill patients. This measurement is crucial in determining whether the observed changes in glucose homeostasis are a risk factor for type 2 diabetes or hallmarks of a novel diabetes subtype.
The finding of a statistically significant association between degree of in-hospital hyperglycemia and prevalence of new-onset diabetes after acute and critical illness suggests that prevention strategies for high-risk patients may need to be considered. Type 2 diabetes is a preventable disease, and prevention programs in the United States, 74 China, 75 and Finland 76 have found that patients allocated to dietary and lifestyle modification had a significantly lower incidence of diabetes than those in control groups. However, it remains to be investigated whether such programs would be useful in reducing the risk of diabetes after acute and critical illness.
This review has several limitations. First, the statistical heterogeneity across studies was high for all the glycemic groups. This may be attributed to different study settings or the timing of glucose measurements across the course of disease. However, we conducted a sensitivity analysis and a series of prespecified subgroup analyses on the effect of disease setting, study duration, and study design to investigate whether these potential confounders could explain the discrepancy across studies. In addition, random effects models were used as the most conservative approach to estimating the prevalence of new-onset diabetes. Second, we were not able to investigate whether the stepwise increase in prevalence of new-onset diabetes was independent of conventional risk factors for type 2 diabetes, such as family history of diabetes, age, sex, body mass index, physical activity, and socioeconomic status. 42, [77] [78] [79] [80] [81] However, this is a common limitation of systematic reviews, which are secondary analyses of the literature. Third, not all included studies screened for undiagnosed diabetes at the time of hospitalization, hence it is possible that a fraction of the patients included in the analyses may have had unrecognized diabetes before hospital admission. However, 9 studies did test for hemoglobin A 1c during hospitalization and excluded patients who presented with undiagnosed diabetes. 12, [23] [24] [25] [26] 31, [38] [39] [40] Last, the findings from this review may not be generalizable to all disease settings. Although the meta-analysis included 7 disease settings, it was limited to studies that reported the effect of in-hospital glucose concentration on the prevalence of new-onset diabetes. Furthermore, patients undergoing transplant were excluded from the review because many had end-stage diseases. In addition, the findings of the systematic review were limited to adults only.
CONCLUSION
The degree of in-hospital hyperglycemia in acute and critically ill patients is significantly associated with the prevalence of new-onset diabetes. Patients with severe hyperglycemia have the greatest risk, with 28% developing diabetes after hospital discharge. Pathogenesis of new-onset diabetes after acute and critical illness needs to be investigated in mechanistic and longitudinal prospective studies.
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